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Inﬂammatory activation is associated with a reduced
glucocorticoid receptor alpha/beta expression ratio in
monocytes of inpatients with melancholic major depressive
disorder
LA Carvalho1,5, V Bergink2,5, L Sumaski3, J Wijkhuijs4, WJ Hoogendijk2, TK Birkenhager2 and HA Drexhage4
In this study, we used new technology to investigate whether a coherent pattern of enhanced expression of inﬂammatory and
other immune activation genes in circulating monocytes is found in patients with major depression. Since a high inﬂammatory
state of monocytes might be related to glucocorticoid resistance, we also included the genes for the two isoforms of the
glucocorticoid receptor. For this study, we aimed at ﬁnding a similar coherent pattern of inﬂammatory and immune activation
genes in monocytes of patients with MDD and recruited 47 medication-free melancholic MDD inpatients and 42 healthy controls.
A quantitative-polymerase chain reaction (Q-PCR) monocyte gene expression analysis was performed using a panel of
inﬂammatory-related genes previously identiﬁed as abnormally regulated in mood disorder patients. Selected serum cytokines/
chemokines were assessed using a cytometric bead array. Depressive symptoms were analysed using Hamilton depression scores
(HAMD). Thirty-four of the 47 monocyte inﬂammatory-related genes were signiﬁcantly upregulated and 2 were signiﬁcantly
downregulated as compared to controls, the latter including the gene for the active GRα in particular in those with a high
HAMD score. The reduced GRα expression correlated strongly to the upregulation of the inﬂammatory genes in monocytes.
Serum levels of IL6, IL8, CCL2 and VEGF were signiﬁcantly increased in patients compared to controls. Our data show the
deregulation of two interrelated homoeostatic systems, that is, the immune system and the glucocorticoid system, co-occurring
in major depression.
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INTRODUCTION
Major depressive disorder (MDD) is a biologically and genetically
heterogeneous disorder. Despite advances in understanding
biological correlates of MDD, speciﬁc objective hallmarks are still
lacking. Deﬁning a clear phenotype increases the chance of
ﬁnding speciﬁc disturbances in neurobiology that may beneﬁt
from particular targeted treatments.
In recent years, an increasing body of evidence shows the
involvement of an increased inﬂammatory response system in
MDD1,2 and meta-analysis studies have conﬁrmed the increase of
pro-inﬂammatory cytokines in the circulation of patients.3,4
Several routes have been uncovered through which cytokines
might enter and act in the brain, thereby, making the brain
vulnerable to stress. Indeed pro-inﬂammatory cytokines have
been found to interact with many of the pathophysiological
domains that characterize psychiatric behaviour, such as with
neurotransmitter metabolism, neuroendocrine function and
synaptic plasticity and behaviour.5 Further, low intravenous doses
of endotoxin increase the level of these cytokines and induce
depressive symptoms.6 Depressive symptoms can also be induced
by interferon-alpha treatment.7 In contrast, blocking these
cytokines, for example, using anti–tumour necrosis factor (TNF)
therapy, results in a markedly improved mood in treatment-
resistant depressed patients.8
This makes cytokines prime candidates for recording immune
neurobiological disturbances underpinning major mental disor-
ders.However, one must take into account that cytokine levels in
serum or plasma are strongly confounded by age, gender, socio-
economic status, metabolic syndrome, visceral obesity, smoking,
exercise, poor-rated self-health and medication. Cytokine levels in
serum and plasma are also more deeply affected by environ-
mental factors and present high inter-individual variation.
Accordingly, we have focused our investigations not only on
cytokines but also on important cellular producers of these
cytokines, namely monocytes and macrophages. Supporting this
approach, our group has identiﬁed a coherent pattern of
enhanced expression of inﬂammatory and other immune activa-
tion genes in circulating monocytes of patients with mood
disorders other than MDD, namely bipolar disorder and post-
partum psychosis.9–11
For this study, we aimed at ﬁnding a similar coherent pattern of
inﬂammatory and immune activation genes in monocytes of
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patients with MDD. We have included severely depressed inpa-
tients, almost exclusively with melancholic features, medication
free and report outcomes of a quantitative polymerase chain
reaction (Q-PCR) study of monocytes in these patients tested for
the genes previously found to be upregulated in bipolar disorder,
schizophrenia and related endocrine autoimmune diseases.10–15
We compared outcomes of gene expression in monocytes with
circulating levels of some monocyte/macrophage related cyto-
kines/chemokines and vascular endothelial growth factor (VEGF),
an angiogenic protein and the adhesion molecule s-ICAM all of
which have been implicated in major psychiatric conditions.
It has been hypothesized that the increased inﬂammatory
response system found in severely depressed patients is
responsible for the hypothalamic-pituitary-adrenal axis hyperac-
tivity also found in some patients, possibly due to a cytokine-
induced reduction of glucocorticoid receptor (GR) sensitivity.16,17
In accordance, we have previously reported that increased
activation of the inﬂammatory system co-occurs with hyperactivity
of the hypothalamic-pituitary-adrenal axis18 and with impaired GR
sensitivity19 in treatment-resistant depressed patients. Glucocorti-
coids modulate a wide variety of immune cell functions, like
cytokine and adhesion molecule expression, immune cell trafﬁck-
ing, maturation and differentiation. Glucocorticoids are able to
shift the immune responses from a pro-inﬂammatory to an anti-
inﬂammatory cytokine pattern.20,21 Glucocorticoids bind to two
receptors: the GR and the mineralocorticoid receptor. The primary
receptor for glucocorticoids in immune cells is the GR, which is
located in the cytoplasm in an inactive multi-protein complex
form. Cloning of the human GR has identiﬁed two isoforms,
termed GRα and GRβ, which originate from alternative splicing of
the GR primary transcript.22,23 The GRβ lacks the ability to bind
glucocorticoids and seems to function as an inhibitor of GRα-
mediated transcriptional activation through the formation of GRα/
GRβ heterodimers.24,25 In this study, we additionally included in
the Q-PCR study of the monocytes of the MDD patients both the α
and β isoform of the GR receptor.
MATERIALS AND METHODS
Participants
This study was approved by the Medical Ethical Committee of the
Erasmus MC Rotterdam (Ethics number MEC-2003-100-5). After study
procedures had been fully explained, all subjects provided written
informed consent.
Forty-seven (n= 47) patients with MDD were recruited from the
depression inpatient unit of the Department of Psychiatry of the Erasmus
Medical Centre in Rotterdam, the Netherlands. All patients were diagnosed
according to the DSM-IV-TR using the Structural Clinical Interview for
Disease (SCID-1). Severity of depression was analysed using Hamilton
depression questionnaire version 17. We used stringent exclusion criteria
to avoid the possibility that medication or a physical disorder could
inﬂuence gene expression. All patients had to be antidepressant
medication free for at least one week before blood withdrawal. Blood
was withdrawn in the morning between 0800 and 1000 hours.
Benzodiazepines were allowed on the dose of 1–3mg per day. One
patient continued with haloperidol. Patients were excluded if they met the
following criteria: were incapable of understanding the information and to
give informed consent; unable to read or write, mental retardation
(IQo80); bipolar I or II disorder, schizophrenia or other primary psychotic
disorder; if they had drug/alcohol dependence for the last 3 months,
serious medical illness; women: pregnancy or possibility for pregnancy and
no adequate contraceptive measures, breastfeeding.
Forty-two gender-matched healthy controls (HC) were recruited from
the same community. Gender-matched HC (n=42) were recruited via
enrolling laboratory staff, medical staff and medical students. The inclusion
criteria for the HC were an absence of any major Axis I psychiatric disorder
such as schizophrenia, psychotic disorder, mood disorder, anxiety disorder
or substance related disorder according to DSM-IV criteria and no history
of a severe medical illness. HC had to be in self-proclaimed good health
and free of any obvious medical illness for at least two weeks prior to the
blood withdrawal, including acute infections and allergic reactions. HC
were also free of medications including oral contraceptives.
Blood collection and preparation
Blood was collected in clotting tubes for serum preparation (stored
at –80 °C) and in sodium–heparin tubes for immune cell preparation. From
the heparinized blood, peripheral blood mononuclear cell suspensions
were prepared by low-density gradient centrifugation via Ficoll-Paque
PLUS (GE Healthcare, Uppsala, Sweden), as described previously in detail26
within 8 h to avoid erythrophagy-related activation of the monocytes.
Peripheral blood mononuclear cells were frozen in 10% dimethylsulph-
oxide and stored in liquid nitrogen. This enabled us to test immune cells of
patients and controls concomitantly at a later stage.
Isolation of monocytes and RNA
The use of one single cell type (i.e. monocytes instead of peripheral blood
mononuclear cell) reduces the ranges of factors that may lead to inconsistency
in the results due to differential gene expression per cell type. CD14 positive
monocytes were isolated from frozen peripheral blood mononuclear cells by
magnetic cell sorting system (auto MACS Pro, MiltenyiBiotec, B.V., Bergisch
Gladbach, Germany). The viability and purity of monocytes was >95%
(determined by morphological screening after Trypan Blue staining and ﬂow
cytometry analysis). The average viability was 97.1±3.5 and the purity of
monocytes 97±2.2%. RNA was isolated from puriﬁed monocytes using the
RNAeasy minikit according to the manufacturer’s instructions (Qiagen, Hilden,
Germany).27 On average, monocytes cell yield after isolation was 2.2±1.0 ×
106 and quantity of RNA in monocytes 3.3 ±1.6 μg.
RT-qPCR
One μg of RNA was reversed-transcribed using the High Capacity cDNA kit
(Applied Biosystems, Foster City, CA, USA). qPCR was performed using
TaqMan Arrays, format 48 (Applied Biosystems), according to the
manufacturer’s protocol and validated against the single RT-qPCR method.
Per ﬁll port 400 ng of cDNA (converted from total RNA) was loaded. PCR
ampliﬁcation was performed using an Applied Biosystems Prism 7900HT
sequence detection system with TaqMan Array block.Thermal cycler
conditions were 2 min at 50 °C, 10min at 94.5 °C, 30 s at 97 °C and 1min at
59.7 °C for 40 cycles. Expression values were calculated using the
comparative threshold cycle method.
Serum cytokine/chemokine determination
Multiple serum cytokines were measured using a multiplex array approach:
the Cytometric Bead Array kit (CBA, Bender MedSystems, Burlingame, CA,
USA) according to the manufacturer’s protocol. Samples were analysed in a
BD FACS Canto II ﬂow cytometer (BD Biosciences, San Jose, CA, USA) with
the Flowcytomix Pro 2.3 Software (eBioscience, Vienna, Austria). We
determined serum cytokine levels of the monocyte/macrophage cytokines
CCL2, IL-1β, IL6, IL8, VEGF, and soluble adhesion molecule (s-ICAM). The
CBA was not sensitive enough to reliably detect IL-1β and IL6. Sensitivity of
the kit is provided in Supplementary Table 1. For both patients and
controls, samples that were below the sensitivity of the method were
replaced by the lowest sensitivity of the kit. We are aware of the
insensitivity of the kit for these cytokines, however, we did not have spare
serum to re-analyse these cytokines separately.
Statistical analysis
Statistical analyses were performed using SPSS version 21 and graphpad
prism 5. Dendogram was obtained from Pearson correlation in SPSS. Heat
map was built using Treeview.28 For sample characteristics, categorical
data were evaluated using Fisher’s exact test and continuous variables
using a two-sample t-test. Continuous variables are expressed as the
mean± standard error. The Mann–Whitney U test was used to compare
levels of nonparametric parameters (serum/cytokines). For gene expres-
sion, P was tested by univariate analysis of covariance (ANCOVA) vs control
subjects; age and gender are included in this model. Statistical analysis on
the gene expression data in monocytes and geometric mean of the FC was
performed using DataAssist version 3.0 (Applied Biosystems, Life
Technologies Corporation). Correlations were determined via Spearman
rank correlation coefﬁcients. All hypotheses were tested with an alpha of
0.05 (two-sided). Multiple testing correction was applied using Simes’
correction, which is an improved version of Bonferroni.29,30
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RESULTS
Patients
Data is expressed as mean (range). HC were younger than MDD
patients (HC = 49 (3131–74), MDD=54 (32–82), Po0.005). There
were no signiﬁcant differences in gender distribution (HC = 21
males (50%), MDD=20 males (43%)). MDD patients had a mean
Hamilton depression rating scale (HAMD17) score of 24.4 (18–30),
and on average, one previous depressive episode (range 0–4). All
patients had melancholic features according to DSM-IV criteria
using SCID-1. At the time of blood sampling, all MDD patients
were drug-free for at least one week. After blood drawn,
participants then went on to go on a clinical trial for which the
results have been reported elsewhere.31
Previous medication included (in numbers): 37 SSRI/SNRI, MAOi
2, tri/tetracyclic 9, dual inhibitor 10, benzodiazepines 36, typical
antipsychotics 8, atypical antipsychotics 8. Only two MDD patients
previously took MAOi (n= 2) and presented higher levels of IL1β
(no MAOi = 41.6 ± 3.8, MAOi = 18.0 ± 5.8, P= 0.001), higher PDE4B
(no MAOi = 12.5 ± 2.1, MAOi = 2.2 ± 0.3, P= 0.001), higher MAFF (no
MAOi = 1.11 ± 0.15, MAOi = 0.30 ± 0.004, P= 0.001) and higher TNF
expression (no MAOi = 10.9 ± 2.2, MAOi = 0.33 ± 0.04, P= 0.001)
than those who have never taken MAOi (n= 45). Despite
the statistical signiﬁcance of these ﬁndings, it might not have
clinical relevance due to the low number of patients in the
comparison group. Finally, MDD patients who previously took
atypical antipsychotics (n= 7) had lower IL1β in the serum
(no atypical_AP = 21.4 ± 4.1, atypical_AP = 4.2 ± 0.001, P= 0.001)
compared to those who have never taken them (n= 40). No other
differences were found.
RT-PCR analysis of monocytes of major depression patients
We determined the monocyte gene expression of 47 genes,
including the genes examined previously in patients with bipolar
disorder and schizophrenia,10,11 postpartum psychosis12 and
inﬂammatory disorders, such as diabetes,13 autoimmune thyroid
disease15 and Sjögren’s disease.14 Finally, we also measured the
two splice variants of the GR (GRα and GRβ).
We ﬁrst performed a cluster analysis for monocyte gene
expression (Figure 1b). Two main clusters were identiﬁed—a
large cluster 1 and a smaller cluster 2. Cluster 1 genes included
most of the well-known pro-inﬂammatory mediators (e.g. IL1A,
IL1B, IL6, PTX3, TNF, PDE4B and PTGS2). The smaller cluster 2
genes included mainly chemotaxis (CCL2, CCL7) and metabolic
(DHRS3, FABP5) genes. Notably, the gene clusters extensively
overlapped with the previously identiﬁed monocyte gene
Figure 1. (a) Q-PCR analysis of monocytes of MDD patients (n= 47) as compared to healthy control (HC) (n= 42) values, set at onefold. The
quantitative value obtained from Q-PCR is a cycle threshold (CT). The fold change values between different groups were determined from
normalized CT values (CT gene–CT reference gene ABL), by the ΔΔCT methods (2−ΔΔCT, user Bulletin 2, Applied Biosystems, Foster City, CA,
USA) as per DataAssist software. Data were standardized to the HC (thus the HC were used as the calibrator). The fold change of the HC is
therefore 1. For gene expression, P was tested by univariate analysis of covariance (ANCOVA) vs control subjects; age and gender are included
in this model. (b) Heat map of gene correlation, data represent Spearman’s correlation coefﬁcients, tested on the relative mRNA expression.
Signiﬁcant positive correlations (Po0.05) are given by the red scale (darkest red are correlations >0.5), signiﬁcant negative correlations are
given by the green scale. Lighter ﬁelds are not signiﬁcant. FC, fold change; MDD, major disorder. P values are shown after Simes’ correction.
Bold FC are signiﬁcantly upregulated.
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expression clusters described in the monocytes of bipolar,
schizophrenia and postpartum psychosis patients (Drexhage
et al.10 and Bergink et al.12).
Figure 1a additionally shows that in patients with MDD,
monocyte inﬂammatory/immune gene expression was consis-
tently upregulated compared to HC (apart from the GRα and
HSP70 genes): 34 out of 47 (72%) immune-related genes were
signiﬁcantly upregulated after Simes’ correction for multiple
comparisons. The upregulated genes were found mainly within
cluster 1 (26/29, 90%), whereas in cluster 2, eight out of 14 (57%)
of the genes were upregulated (see Figures 1a and b).
GRα and GRβ expression in monocytes and their relation with the
expression of cluster 1 and cluster 2 inﬂammatory genes
With regard to the GRα and GRβ expression, we found a signiﬁcant
downregulation of the active GRα in MDD patients (F(1,86) = 11.99,
P=0.001), whereas there was a trend for an upregulation of the
inactive GRβ, that did not reach statistical signiﬁcance. To test for the
relationship between the splice variants of the GR and the
inﬂammatory gene expression, we correlated GRα and GRβ
expression separately to the other tested genes (Table 1). The
downregulation of GRα negatively and signiﬁcantly correlated with
the overexpression of a large proportion of the monocyte activation
genes of cluster 1 (26/30) and of cluster 2 (8/13). GRβ overexpression
positively and signiﬁcantly correlated with the overexpression of
27/30 cluster 1 genes and 8/13 cluster 2 genes (Table 1).
Inﬂammatory cytokines/chemokines
To investigate whether the activated inﬂammatory response
system as found via the gene activation of the circulating
monocytes of MDD patients was also reﬂected in higher serum
levels, we measured a selected panel of inﬂammatory cytokines/
chemokines produced by monocytes IL1β, IL6, IL8, CCL2 and VEGF
in the serum of the MDD patients and compared these to levels
found in HC. We found evidence for increased levels of IL6
(P= 0.04), IL8 (P= 0.004), CCL2 (P= 0.04) and VEGF (P= 0.028) in the
serum of MDD patients (as compared to HC), but not of IL1β after
Simes’ multiple test correction (Figure 2).
Correlations between gene expression levels in circulating
monocytes and serum levels of cytokines
To understand potential sources of increased serum cytokines/
chemokines levels, we correlated serum cytokine/chemokine
protein levels to monocyte expression levels of the corresponding
genes. Interestingly there was a negative correlation between
CCL2 levels in serum with CCL2 gene expression in monocytes
(−0.271, P= 0.047) and between serum IL1β with IL1B gene
expression in monocytes (−0.259, P= 0.059). There were no other
signiﬁcant correlations between serum protein and gene expres-
sion. This reﬂects a complex picture of inﬂammatory regulation
with the possible involvement of other cell types.
We additionally investigated the relationship between the
expression of the glucocorticoid receptor splice variants (GRα, GRβ)
and the GRα/β expression ratio and the levels of cytokines in
the serum.
Interestingly, GRα expression negatively correlated to IL8 serum
levels (S =− 0.389, P= 0.008); GRβ expression in monocytes
correlated negatively to the CCL2 serum level (S =− 0.309,
P= 0.035), and GRα/β positively correlated to CCL2 serum levels
(S = 0.292, P= 0.046). No other correlation was found between GR
splice variants and levels of cytokines in the serum.
GRα, GRβ and inﬂammatory molecules in monocytes and their
relation with clinical variables
In order to evaluate possible associations between GRα, GRβ and
inﬂammatory parameters with clinical variables, we correlated
gene expression levels in monocytes and the severity of
depression as measured by total HAMD score. There were no
associations with age and gender. As shown in Supplementary
Table 2, GRα and EREG positively correlated to the severity of
depression.
As anxiety is often a main symptom of severe depression, we
also investigated correlations of psychic (item 10) and somatic
anxiety (item 11) as assessed by the Hamilton depression scale
with gene expression levels in monocytes. As shown in Tables 2A
and B, the molecules EREG, CDC42, NMES1, CCL7 and AREG and
GRβ positively and signiﬁcantly correlated with psychic anxiety.
Table 1. Correlation analysis of the GRα and GRβ expression level
compared to expression levels ﬁngerprint genes in monocytes of MDD
patients (n= 47)
GRα correlates to (in MDD) GRβ correlates to (in MDD)
Spearman's rho Corrected
P-value
Spearman's rho Corrected
P-value
GRα 1
GRβ −0.253 0.073
CCL20 −0.475 0.002 0.456 0.002
IL1β −0.513 0.002 0.500 0.002
EREG −0.534 0.001 0.555 0.001
PDE4B −0.444 0.002 0.458 0.002
CXCL2 −0.601 0.002 0.541 0.002
IL8 −0.525 0.001 0.520 0.001
TNFAIP3 −0.289 0.054 0.304 0.041
BTG3 −0.681 0.002 0.517 0.002
PTX3 −0.572 0.002 0.490 0.002
ADM −0.627 0.002 0.407 0.005
CDC42 −0.731 0.002 0.523 0.002
ATF3 −0.603 0.002 0.588 0.002
MAFF −0.688 0.002 0.513 0.002
BCL2A1 −0.615 0.002 0.497 0.002
IL6 −0.530 0.002 0.532 0.002
MAPK6 −0.570 0.002 0.602 0.002
IL1A −0.433 0.005 0.495 0.002
MXD1 −0.420 0.003 0.394 0.007
PTGS2 −0.474 0.002 0.451 0.002
SERPINB2 −0.450 0.002 0.495 0.002
IFIT3 0.139 0.378 0.193 0.203
NMES1 −0.636 0.001 0.551 0.001
CXCL3 −0.563 0.001 0.465 0.001
IRAK2 −0.685 0.002 0.427 0.004
EGR3 −0.385 0.009 0.616 0.002
DUSP2 −0.465 0.002 0.362 0.014
TNF −0.361 0.013 0.286 0.055
Pu.1 −0.199 0.212 −0.067 0.664
DAP12 −0.017 0.926 −0.003 0.985
DHRS3 −0.123 0.432 0.338 0.023
RGC32 −0.636 0.002 0.551 0.002
CCL2 −0.41 0.005 0.441 0.002
ILR1 0.000 0.997 0.414 0.005
TREM1 −0.052 0.747 0.541 0.002
EMP1 −0.286 0.055 0.375 0.011
THBD −0.298 0.047 0.216 0.154
NAB2 −0.436 0.002 0.119 0.442
CCL7 −0.550 0.002 0.577 0.002
STX1A −0.405 0.005 0.325 0.029
AREG −0.576 0.002 0.329 0.030
PTPN7 −0.197 0.204 0.092 0.555
FABP5 0.122 0.432 0.289 0.054
CD9 −0.367 0.012 −0.219 0.151
HSP 0.716 0.002 −0.169 0.264
IFI27 −0.216 0.168 0.231 0.136
Data show the Spearman’s correlation coefﬁcients and signiﬁcance levels
after Simes’ correction.
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There was no correlation between gene expression of the
molecules tested and somatic anxiety.
In order to understand further the association between
inﬂammatory molecules, GRα, GRβ gene expression levels and
the GRα/β ratio in monocytes and depression severity, we
conducted a linear regression model between the variables that
were signiﬁcantly correlated with HAMD scores in Tables 2A and B.
Table 2A shows linear regression coefﬁcients values of GRα, GRβ,
and the GRα/β ratio in relation to the HAMD score. Model 1 shows
the crude association; model 2 includes age and gender. As can be
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Figure 2. Serum cytokine levels in MDD (n= 47) and HC (n= 42). Data shown are mean± s.e.m. in pg per ml.*PÂ⩽ 0.05 after Simes’ correction.
Table 2A. Linear regression models for the association between GRα, GRβ and GRα/β ratio and total HAMD scores in patients with major depression
(n= 47)
Relationship of GRα, GRβ and GRα/β ratio and HAMD scores adjusted for socio-demographic variables
Standardized regression
coefﬁcients
Unstandardized regression
coefﬁcients
P-values 95% CI
Log GRα
Model 1 −0.284 −0.03 0.050 −0.06 0.001
Model 2 −0.278 −0.029 0.066 −0.062 0.002
Log GRβ
Model 1 0.220 0.048 0.138 −0.016 0.111
Model 2 0.234 0.051 0.112 0.003 0.115
Log GRα/β
Model 1 −0.295 −0.078 0.044 −0.153 −0.021
Model 2 −0.303 −0.080 0.040 −0.032 −0.013
Table 2B. Ordinal regression models for the association between GRα, GRβ, GRα/β ratio, inﬂammatory molecules and psychic anxiety as measured by
item 10 of the HAMD scores in patients with major depression (n= 47) adjustment for age, gender and BMI
Relationship of GRβ and GRα/β ratio and psychic anxiety adjusted for socio-demographic variables
Estimates OR P-values 95% CI
Log GRα 3.902 7943 0.078 −0.441 8.245
Log GRβ −4.834 1.46*, 10−5 0.001 −7.595 −2.073
Log GRAB 1.573 37.41 0.001 0.654 2.493
Log AREG −1.122 0.075 0.009 −1.965 −0.278
Log CDC42 −2.877 0.0013 0.003 −4.799 −0.955
Log NMES1 −0.826 0.149 0.009 −1.445 −0.207
Log CCL7 −1.169 0.067 0.005 −1.979 −0.359
Log EREG −1.290 0.051 0.009 −2.259 −0.320
*P⩽ 0.05. Model 1—Crude association. Model 2—Further adjustment for age, gender and BMI.
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seen in particular, the monocyte GRα/β correlated to the HAMD
score also after adjustment for age, gender and BMI.
Finally, we conducted ordinal regression models between the
individual molecules EREG, CDC42, NMES1, CCL7 and AREG and
GRβ as these genes correlated with psychic anxiety. As shown in
Table 2B, we found the GRα and GRβ gene expression levels, the
GRα/β gene expression ratio, and EREG, CDC42, CCL7, NMES1 and
AREG expression individually predicting the odds of going up one
level in the psychic anxiety scale. We have also conducted a
multiple regression with all the molecules together to see whether
it increased prediction. The only molecule that remained
signiﬁcantly associated was CDC42 (results are not shown).
DISCUSSION
We have assessed an inﬂammatory gene expression proﬁle in
monocytes of melancholic drug-free inpatients with major
depression and evaluated the relationship of this inﬂammatory
expression pattern with the expression of the genes for the active
GRα and the inactive GRβ in the monocytes. The outcomes of our
study show that circulating monocytes overexpress inﬂammatory
genes and underexpress the active GR variant (i.e. the α variant),
suggesting a relative insensitivity of the monocytes for glucocor-
ticoids. Particularly MDD patients with a high HAMD score had the
lowest monocyte GRα expression. Supporting our ﬁndings, MDD
patients had a high inﬂammatory set point of monocyte and high
serum levels of pro-inﬂammatory cytokines and compounds, such
as IL8, IL6, CCL2 and VEGF.
Our study extends and supports previous studies on gene
expression proﬁles in peripheral blood leucocytes in patients with
MDD. Spijker et al.32 used gene expression in peripheral blood
after lipopolysaccharide stimulation and identiﬁed an MDD
signature of seven upregulated genes of which six were related
to the immune system, in particular dealing with cellular
proliferation and differentiation. Segman et al.33 found in a
relative small series of persistent postpartum depression patients,
a gene expression signature of immune, proliferation and repair
genes that was downregulated as compared to controls. Interest-
ingly many of the immune genes found by these authors in their
signature are in our list of tested genes (IFIT and EREG). Belzeaux
et al.34 identiﬁed in a relatively small series of patients a
considerable number of genes and microRNAs deregulated that
are involved in various biological processes, most notably in
nucleotide binding and chromatin assembly. They were able to
select four genes that could predict treatment response. Among
these four genes were TNF and IL1B, which are also in our list of
tested genes. Savitz et al.35 detected a gene signature in
peripheral blood of MDD patients consisting of 12 genes, among
which 2 genes (ADM and TNF) were also in our list of genes.
Network analysis revealed two gene networks, one clearly related
to inﬂammation. Interestingly the inﬂammatory genes in the
signature correlated with the grey matter volume of the caudate
in magnetic resonance imaging.
Our study is congruent with these studies in identifying
important inﬂammatory genes in circulating leucocytes being
discriminative between MDD patients and HC. It also differs from
these studies. First, we solely concentrated on inﬂammatory genes.
We selected a panel of such inﬂammatory genes in previous studies
(see before). The studies of the other investigators included genes
involved in non-inﬂammatory processes, most notably cell pro-
liferation and differentiation. Second, we measured gene expression
not in the entire peripheral blood leucocytes population (containing
around 70–80% lymphocytes), but in a discrete sub-population of
peripheral blood leucocytes only, that is, in monocytes. The
correlates to monocytes in the brain are the microglia, of which it
is known that pro-inﬂammatory activation affects neuronal growth
and synaptic functioning. Microglia is pro-inﬂammatory activated in
major mental disorders.36 Third, we found overexpression of the
inﬂammatory genes in the immune cells similar to that found in
Belzeaux et al.34 and Savitz et al.,35 whereas Segman et al.33 found a
downregulation of genes. It must be noted that we also reported a
downregulation of lymphocyte activity in postpartum psychosis,
while there was strong monocyte activation. Thus, the fact that
these authors used peripheral blood leucocytes instead of
monocytes may explain differences found. Despite these differ-
ences, all these reported gene expression studies point to an
important role of the immune and inﬂammatory system in MDD.
We tested the monocytes for a coherent proﬁle of genes
consisting of two mutually, strongly correlating clusters of genes,
which are also upregulated in monocytes of bipolar patients,
schizophrenia patients and postpartum psychosis patients. Our
study thus underscores the notion already expressed by geneticists
based on outcomes of GWAS studies that there must be common
underlying inborn molecular vulnerabilities for the major mental
disorders,37 some of which might well be inﬂammatory in nature.
Our upregulated gene expression proﬁle in monocytes of
melancholic drug-free inpatients with MDD is composed of a
network of cytokines and pro-inﬂammatory molecules, many of
which have previously been found upregulated when tested at
the protein level in MDD patients.4 In this study, we additionally
found that IL6, IL8, CCL2 and VEGF were signiﬁcantly increased in
the serum of our MDD patients. Interestingly there was a negative
correlation between CCL2 and IL1β levels in serum with the CCL2
and IL1B gene expression in the activated monocytes. This is
suggestive for the idea that the circulating pro-inﬂammatory
activated monocytes are not the source of the elevated cytokines/
chemokines in serum. However, it is also possible that the
activated monocytes are the source, but the elevated cytokines
downregulate the gene production in monocytes in an autocrine
fashion. It is likewise possible that the cytokines are produced by
other inﬂammatory-changed cells, such as endothelial cells or
activated, migrating macrophages in the tissues and that these
elevated cytokines/chemokines downregulate the gene produc-
tion in monocytes in a paracrine function. Indeed our studies
showed that CCL2 levels in serum correlated not only to a reduced
expression of CCL2 message, but also to a reduced expression of
the message for the inactivating GRβ, suggesting a generalized
enhanced sensitivity of the activated monocytes to steroids due to
high levels of CCL2. It is known that CCL2 is primarily produced by
monocytes/macrophages shortly after having inﬁltrated the
tissues and this phenomenon may thus represent an ongoing
mild inﬂammatory monocyte/macrophage response in the tissues
downregulating the inﬂammatory state of circulating monocytes
to control inﬂux. A similar phenomenon can be observed in
monocytes of type 1 diabetic patients.38 The higher serum level of
CCL2 found by us in MDD patients is consistent with our previous
reports on higher serum levels in MDD18 and in mood disorders in
general.10,12 These higher levels of CCL2 underscore the enhanced
migration of monocytes into and through the tissues in major
mental disorders as proposed by the immune theory.
With regard to IL8, the meta-analysis of Dowlati et al. (2009)
concluded that evidence was lacking that IL8 levels were altered
in MDD having evaluated four articles on IL8. IL8 is a cytokine
particularly produced by macrophages when activated by IFN-γ
produced by TH1 cells, the so-called M1 macrophages.39 We found
IL8 clearly raised in our melancholic drug-free MDD inpatients.
Severity and character of the disease may have had a role here.
Serum levels of VEGF have been found largely unaltered in MDD,40
but elevations have been described in more severely ill MDD
patients who are unresponsive to antidepressant treatment,18
MMD with co-morbid borderline personality disorder41 and after
ECT.42 Our data also suggests a role of VEGF in MDD. VEGF is an
angiogenic protein with both neuroprotection and neurotrophic
actions43 and can be produced by monocytes/macrophages.44 We
ourselves have previously shown an involvement of other
neurotrophic factors in mood disorders.18,45,46
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Our study is also the ﬁrst to show that the decreased GRα/GRβ
ratio in major depression occurs in the context of inﬂammatory
activation. Our study agrees and extends that of Matsubara
et al.47 who found reduced GRαmRNA in whole blood of patients
with major depression. Our data also agrees with mounting
evidence suggesting that inﬂammation itself may contribute to
reduced glucocorticoid sensitivity,48 and provide a mechanism
by which this maybe happening in depressed patients. We found
the raised levels of IL8 in the serum of MDD patients to correlate
signiﬁcantly and negatively to the GRα/β ratio of gene expression
in the monocytes. This can be interpreted as: the higher the
production of IL8, the more reduced the glucocorticoid
sensitivity of monocytes. This observation is thus compatible
with the view that inﬂammatory cytokines can cause glucocorti-
coid resistance in our patients. Indeed, in conditions of chronic
inﬂammation, pro-inﬂammatory cytokines can cause GR
resistance49 by reducing GR afﬁnity,16 by inhibiting GR transloca-
tion, by hormone-induced GR-mediated gene transcription,50,51
and by promoting expression of the inactive GRβ isoform of the
GR.17 In addition, cytokine-mediated inﬂammatory processes
have an important role in the development of GR resistance in
the context of depression. Of particular relevance to this study,
pro-inﬂammatory cytokines can not only induce glucocorticoid
resistance in immune cells, but also in cells of the hypothalamic-
pituitary-adrenal axis and therefore result in hyperactivity of the
axis.51,52 In fact, studies have demonstrated that treatment with
pro-inﬂammatory cytokines induces a decrease in GR function as
evidenced by decreased sensitivity to the effects of glucocorti-
coids on functional endpoints and decreased GR afﬁnity for
ligand.48,53
A limitation of our approach is that we have made in our
experimental design a selection of differentially expressed genes
by selecting in previous whole genome analysis on monocytes of
patients with major mental illnesses only the highly over- and
underexpressed genes (more or less than 3.5-fold), which were
clearly involved in inﬂammation and inﬂammatory processes.
Although this approach proved fruitful in detecting the inﬂam-
matory signature pattern of two clusters of genes as described
here and previously, we may have missed important causal genes
for the inﬂammatory set points.
In conclusion, melancholic drug-free inpatients with major
depression have an increased pro-inﬂammatory monocyte set
point and increased levels of IL6, IL8, CCL2 and VEGF. The pro-
inﬂammatory activation involves a decreased GRα/GRβ ratio,
which is associated with the severity of the melancholic
depression. Collectively, our data highlight a model for melan-
cholic depression by which an abnormal set point of the neuro-
immuno-endocrine axis leads to increased activity of the
macrophage system; and suggest a mechanism by which
inﬂammation can reduce glucocorticoid sensitivity in major
depression.
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